Metabolic and Genetic Screening of Electromagnetic Hypersensitive Subjects as a Feasible Tool for Diagnostics and Intervention
Figure 3
Distribution of specific organ comorbidities (a) and sensitivity-related illness-SRI comorbidities (b) registered in the case history of the group of patients self-reporting electromagnetic hypersensitivity (EHS, ). Data are expressed as percentage of the total patient group, for patients affected by each single category of organ pathologies (a), and by each SRI (b), specifically multiple chemical sensitivity (MCS) or suspected MCS (sMCS), chronic fatigue syndrome (CFS), fibromyalgia (FM), and posttraumatic stress disorders (PTSD).
